Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + opioid
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Transdermal, Intramuscular, Subcutaneous, Intrathecal
01
Overview
A combination therapy using duloxetine (a serotonin-norepinephrine reuptake inhibitor) and opioid medications for pain management. This combination is primarily used for treating various pain conditions, particularly postoperative pain and cancer-related neuropathic pain. The dual mechanism targets both monoamine reuptake inhibition and opioid receptor activation to provide pain relief.
02
Targets
DOR (Opioid Receptor Delta 1)SERT (Sodium-dependent serotonin transporter)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on duloxetine + opioid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + opioid.